JAK2 Mutation Reagent Kits, Supplies, and Consumables

The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 22 is seeking to procure JAK2 Mutation Testing Reagents and Supplies for in-house patient testing at the VA Greater Los Angeles Healthcare System. The solicitation specifically requests reagents compatible with their existing Applied Biosystem 7500 Analyzer System to detect JAK2 gene mutations, particularly the V617F mutation, using RT-PCR or High-Resolution Melt Analysis methods. Vendors must be an Original Equipment Manufacturer, authorized dealer, distributor, or reseller and provide new equipment with appropriate documentation, demonstrating compliance with specific brand name or equal technical specifications including a minimum Limit of Detection of 0.061%. The evaluation will be based on the lowest-priced quotation that meets all salient characteristics and technical requirements. Electronic quotes must be submitted to Contracting Specialist Samuel Han by June 25, 2025, at 1:00 PM Pacific Time.

This procurement does not utilize any set-aside designations and will be conducted through full and open competition under Simplified Acquisition Procedures. The primary product referenced is the Qiagen ipsogen JAK2 MutaQuant Kit with an estimated annual quantity of 67 units, though the schedule includes provisions for up to a 50% quantity increase based on operational needs. The contract will be a single Firm-Fixed Price award with a one-year period of performance, requiring items to ship within 72 hours of order placement. Performance will occur at the Veterans Administration facility in Los Angeles, California 90073. The solicitation falls under NAICS code 325413 for In-Vitro Diagnostic Substance Manufacturing and includes requirements for DNA sample processing from whole blood or bone marrow samples with a one-year shelf life specification.